133 related articles for article (PubMed ID: 7295339)
21. Morphological transformation and catalase activity of Syrian hamster embryo cells treated with hepatic peroxisome proliferators, TPA and nickel sulphate.
Mikalsen SO; Holen I; Sanner T
Cell Biol Toxicol; 1990 Jan; 6(1):1-13. PubMed ID: 2334865
[TBL] [Abstract][Full Text] [Related]
22. Correlation between the cellular level of long-chain acyl-CoA, peroxisomal beta-oxidation, and palmitoyl-CoA hydrolase activity in rat liver. Are the two enzyme systems regulated by a substrate-induced mechanism?
Berge RK; Aarsland A
Biochim Biophys Acta; 1985 Nov; 837(2):141-51. PubMed ID: 2864957
[TBL] [Abstract][Full Text] [Related]
23. Effect of clofibrate treatment on aconitase activity in rat liver and other tissues.
Antonenkov VD; Panchenko LF
Int J Biochem; 1985; 17(6):741-4. PubMed ID: 4029493
[TBL] [Abstract][Full Text] [Related]
24. Three hypolipidemic drugs increase hepatic palmitoyl-coenzyme A oxidation in the rat.
Lazarow PB
Science; 1977 Aug; 197(4303):580-1. PubMed ID: 195342
[TBL] [Abstract][Full Text] [Related]
25. Translactational induction of CYP4A expression in 10.5-day neonatal rats by the hypolipidemic drug clofibrate.
Simpson AE; Brammar WJ; Pratten MK; Elcombe CR
Biochem Pharmacol; 1995 Dec; 50(12):2021-32. PubMed ID: 8849329
[TBL] [Abstract][Full Text] [Related]
26. Subcellular distribution and properties of a clofibrate-induced aldehyde dehydrogenase from rat liver.
Panchenko LF; Pirozhkov SV; Antonenkov VD
Biochem Pharmacol; 1985 Feb; 34(4):471-9. PubMed ID: 3970718
[TBL] [Abstract][Full Text] [Related]
27. Effects of N-(4-methylbenzylthiocarbonyl)-L-phenylalanine (KF 1492), a new hypolipidemic drug, and clofibrate on lipids metabolism.
Ishii A; Deguchi T; Marumo H; Tanaka M
J Pharmacobiodyn; 1983 Mar; 6(3):170-6. PubMed ID: 6410039
[TBL] [Abstract][Full Text] [Related]
28. [Effects of several antilipemic agents on the activity of liver microsomal enzymes].
Mounié J; Goudonnet H; Escousse A; Truchot RC
J Pharmacol; 1986; 17(3):308-15. PubMed ID: 3491930
[TBL] [Abstract][Full Text] [Related]
29. A quantitative analysis of fine structure and drug metabolism in livers of clofibrate-treated young adult and retired breeder rats.
Anthony LE; Schmucker DL; Mooney JS; Jones AL
J Lipid Res; 1978 Feb; 19(2):154-65. PubMed ID: 632678
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the effects of the hypolipidaemic agents ICI53072 and clofibrate with those of phenobarbitone on liver size, blood flow and DNA content in the rat.
Berman JS; Hiley CR; Wilson AC
Br J Pharmacol; 1983 Mar; 78(3):533-41. PubMed ID: 6839062
[TBL] [Abstract][Full Text] [Related]
31. 780 SE: a new type of hypolipemic agent. Comparative assays in rats.
Duhault J; Boulanger M; Beregi L; Sicot N; Bouvier F
Atherosclerosis; 1976; 23(1):63-72. PubMed ID: 1078395
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of liver glutathione S-transferase activity in rats by hypolipidemic drugs related or unrelated to clofibrate.
Foliot A; Touchard D; Mallet L
Biochem Pharmacol; 1986 May; 35(10):1685-90. PubMed ID: 3707598
[TBL] [Abstract][Full Text] [Related]
33. Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: comparison with CPIB.
Reddy J; Svoboda D; Azarnoff D
Biochem Biophys Res Commun; 1973 May; 52(2):537-43. PubMed ID: 4711169
[No Abstract] [Full Text] [Related]
34. Decrease of superoxide dismutase and glutathione peroxidase in liver of rats treated with hypolipidemic drugs.
Ciriolo MR; Mavelli I; Rotilio G; Borzatta V; Cristofari M; Stanzani L
FEBS Lett; 1982 Aug; 144(2):264-8. PubMed ID: 7117540
[No Abstract] [Full Text] [Related]
35. Enhancement of NAD-linked isocitrate dehydrogenase activity in rat liver by clofibrate feeding.
Schön HJ; Kremser K; Prager C; Kramar R
Biochem Pharmacol; 1991 Jun; 41(11):1773-5. PubMed ID: 2043166
[TBL] [Abstract][Full Text] [Related]
36. Selective increase in acylation of 1-acylglycerophosphorylcholine in livers of rats and mice by peroxisome proliferators.
Kawashima Y; Hirose A; Kozuka H
Biochim Biophys Acta; 1984 Apr; 793(2):232-7. PubMed ID: 6712968
[TBL] [Abstract][Full Text] [Related]
37. Effects of tiadenol and clofibrate on plasma post heparin lipolytic hepatic, extrahepatic and monoglyceride hydrolase activities in rats with hypertriglyceridemia induced by a sucrose rich diet.
Gutman R; Basílico MZ; Chicco A; de Rodi MA; Nusimovich B; Lombardo YB
Horm Metab Res; 1985 Apr; 17(4):169-75. PubMed ID: 4007766
[TBL] [Abstract][Full Text] [Related]
38. Clofibrate treatment in pigs: effects on parameters critical with respect to peroxisome proliferator-induced hepatocarcinogenesis in rodents.
Luci S; Giemsa B; Hause G; Kluge H; Eder K
BMC Pharmacol; 2007 Apr; 7():6. PubMed ID: 17437637
[TBL] [Abstract][Full Text] [Related]
39. Effects of tiadenol and di-(2-ethylhexyl)phthalate on the metabolism of phosphatidylcholine and phosphatidylethanolamine in the liver of rats: comparison with clofibric acid.
Mizuguchi H; Kudo N; Ohya T; Kawashima Y
Biochem Pharmacol; 1999 Apr; 57(8):869-76. PubMed ID: 10086319
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological study of hydroxy bis-[2-(p-chlorophenoxy)-isobutyric acid] aluminium. I. The effect of hydroxy bis-[2-(p-chlorophenoxy)-isobutyric acid] aluminum on lipid metabolism in normal rats.
Tomita T; Takeshita R; Nagakura T; Hayashi E
Jpn J Pharmacol; 1973 Jun; 23(3):281-7. PubMed ID: 4541943
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
